Cytomegalovirus Clinical Trial
Official title:
A Dose Escalation Study to Assess the Safety and Immunogenicity of Four Live Attenuated Human Cytomegalovirus(HCMV) Vaccines in Healthy Adults Without Prior Immunity.
Verified date | May 2015 |
Source | CMV Research Foundation |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this research study is to test the safety and tolerability of four new investigational Cytomegalovirus (CMV) vaccines (Towne-Toledo 1, 2, 3, 4) in healthy male volunteers who are CMV negative. CMV is a common virus, infecting 50-80% of adults in the United States by the age of twenty-one. CMV does not usually cause illness in adults or children. However, CMV can be a cause of deafness and mental retardation in a child if a mother is infected during pregnancy. It also can be a serious illness in patients with impaired immunity (decreased ability to fight infection).
Status | Completed |
Enrollment | 36 |
Est. completion date | October 2014 |
Est. primary completion date | October 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 30 Years to 50 Years |
Eligibility |
Inclusion Criteria: - a) Healthy male adult, between the ages of 30 to 50 years with no children <18 years of age at home and in a stable sexual or household relationship with an individual who must be CMV seropositive, non-pregnant, not planning a pregnancy within one year and not currently breastfeeding. b) HCMV seronegative. c) HIV seronegative. d) Hepatitis B surface antigen negative. e) No evidence of active hepatitis C infection by serologic evaluation. f) HCMV culture negative (to be determined by shell vial or routine culture of urine, blood and saliva collected at the screening visit). g) Agrees to abstain from sex or to use condoms during intercourse for 52 weeks following vaccination. h) Available by telephone or pager for one year following vaccination. i) Willing and able to comply with the requirements of the protocol and to properly complete participant diaries. j) Signed informed consent and completed social/demographic questionnaire. k) Willing to forego blood, bone marrow or whole organ donation for 1year post vaccination. l) Willing to forego enrollment in studies of other investigational agents for one year following vaccination. Exclusion Criteria: 1. History of immunodeficiency or any ongoing serious disease such as cancer, autoimmune disease, HIV infection, chronic renal failure (whether or not on dialysis), or diabetes. 2. Significant acute or chronic infection at the time of vaccination. 3. Household contact with an immunosuppressed individual. 4. History of anaphylaxis or severe vaccine reaction. 5. Vaccination with a live vaccine within the past month or an inactivated vaccine within two weeks prior to vaccination, or plan to receive any vaccine within two months following vaccination. 6. Seropositive sexual partner who desires to become pregnant within one year following vaccination, currently is pregnant, or is currently breast feeding. 7. Has a close contact who is CMV seronegative or who is ineligible or chooses not to participate in the study. 8. Received blood products in proceeding three months or expects to receive blood products within the following year. 9. A childcare provider. 10. A health care provider who routinely comes in contact with pregnant women or immunologically compromised persons. 11. Any condition which, in the opinion of the investigator, may interfere with adherence to the protocol or make it inadvisable to enroll the participant. 12. Currently participating in a study of any other experimental or investigational agent, or has participated in such a study within a month of vaccination. 13. Previous vaccination with an investigational HCMV vaccine. 14. Treatment with excluded antiviral or immunosuppressive drugs (Appendix D) within one month prior to vaccination. 15. Expected use of antiviral or immunosuppressive agents within two months following vaccination. 16. Any screening safety laboratory value that is outside normal limits of the laboratory normal range (screening laboratory tests may be repeated if minor abnormalities or possible laboratory errors are noted). |
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
United States | Virginia Commonwealth University | Richmond | Virginia |
Lead Sponsor | Collaborator |
---|---|
CMV Research Foundation | International AIDS Vaccine Initiative |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety | To evaluate the safety and tolerability, in adults without prior HCMV immunity (seronegative), of four live attenuated HCMV investigational vaccines at each of three dose levels. | 2 years | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01248598 -
The Prevelance Rate of Human Cytomegalovirus (HCMV), Epstein-Barr Virus (EBV) and Human Herpes Virus (HHV-6) in a Saliva of the Patient With Periodantitis
|
N/A | |
Active, not recruiting |
NCT05575492 -
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age
|
Phase 1/Phase 2 | |
Recruiting |
NCT03665675 -
Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT
|
Early Phase 1 | |
Completed |
NCT00456664 -
CMV Disease and IRIS in HIV-1 Infected Persons
|
N/A | |
Completed |
NCT04840199 -
A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.
|
Phase 2 | |
Active, not recruiting |
NCT05397223 -
A Study of Modified mRNA Vaccines in Healthy Adults
|
Phase 1 | |
Completed |
NCT02452229 -
Review of Human Herpes Viruses in Burns
|
N/A | |
Completed |
NCT01160081 -
Seroprevalence Study of Hepatitis A, Varicella-Zoster, Cytomegalovirus, Herpes Simplex and Bordetella Pertussis
|
N/A | |
Completed |
NCT00467532 -
Effect of Burn Size on Cytomegalovirus Reactivation and Correlates of T Cell Immune Function in Burned Patients
|
N/A | |
Terminated |
NCT03127787 -
Clinical Performance Evaluation of DxN CMV Assay
|
||
Completed |
NCT00366717 -
Cytomegalovirus Reactivation in Cancer Patients Receiving Chemotherapy
|
N/A | |
Completed |
NCT00815802 -
Detection of Human Cytomegalovirus in the Saliva
|
N/A | |
Completed |
NCT01646645 -
Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 2 | |
Suspended |
NCT00668798 -
Cytomegalovirus (CMV) Transmission by Frozen Breast Milk in Preterms
|
N/A | |
Completed |
NCT00214240 -
The Impact of Cytogam® on Time to Viral Load Reduction in Kidney or Kidney/Pancreas Transplant Recipients With Clinical CMV Disease
|
N/A | |
Completed |
NCT00330018 -
Valganciclovir in Prevention of Cytomegalovirus (CMV) Reactivation Following Allogeneic-Stem Cell Transplantation (SCT)
|
Phase 3 | |
Completed |
NCT02083042 -
Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Kidney Transplant Recipients
|
N/A | |
Completed |
NCT01895049 -
Comparison Between Two Tacrolimus-based Immunosuppressant Regimens and Induction With Thymoglobulin in Kidney Transplants From Deceased Donors With Expanded Criteria
|
Phase 4 | |
Completed |
NCT01162330 -
The Benefits Feasibility and Acceptability of Extended Screening Testing in Newborn Babies Who Are Referred for Further Hearing Assessment
|
N/A | |
Completed |
NCT01008540 -
Prospective Multicentric Study of Cytomegalovirus Resistance in Transplant Patients and Bone Marrow Recipients
|
N/A |